Literature DB >> 25279433

Indication-specific pricing for cancer drugs.

Peter B Bach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25279433     DOI： 10.1001/jama.2014.13235

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  30 in total

1.  Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.

Authors:  Peter B Bach
Journal:  Oncologist       Date:  2015-08-11

2.  Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

Authors:  Jorge Mestre-Ferrandiz; Néboa Zozaya; Bleric Alcalá; Álvaro Hidalgo-Vega
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

Review 3.  Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients.

Authors:  H J Deeg
Journal:  Bone Marrow Transplant       Date:  2015-06-08       Impact factor: 5.483

4.  Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation.

Authors:  Feng Xie
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

5.  Pediatric Orphan Drug Indications: 2010-2018.

Authors:  Lauren Kimmel; Rena M Conti; Anna Volerman; Kao-Ping Chua
Journal:  Pediatrics       Date:  2020-03-03       Impact factor: 7.124

6.  Linking the Price of Cancer Drug Treatments to Their Clinical Value.

Authors:  Lucia Gozzo; Andrea Navarria; Valentina Drago; Laura Longo; Silvana Mansueto; Giacomo Pignataro; Americo Cicchetti; Salvatore Salomone; Filippo Drago
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

7.  Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers.

Authors:  Tammy T Hshieh; Wooram F Jung; Laura J Grande; Jiaying Chen; Richard M Stone; Robert J Soiffer; Jane A Driver; Gregory A Abel
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

8.  Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.

Authors:  Scott K Sherman; Joel J Lange; Fadi S Dahdaleh; Rahul Rajeev; T Clark Gamblin; Blase N Polite; Kiran K Turaga
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

9.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

10.  Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Authors:  Daniel A Goldstein; Bilal B Ahmad; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.